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ABSTRACT

The presently-disclosed subject matter includes light-activated ruthenium compounds. In some embodiments the compounds release one or more ligands when exposed to light,
and in specific embodiments the light includes a wavelength
of about 500 nm to about 1000 nm. The present compounds
can also comprise an overall charge, wherein the overall
charge can be a positive overall charge or a negative overall
charge. Further still, embodiments include methods of treating cancer in a subject by administering a compound and then
exposing a site of the subject to light.
34 Claims, 14 Drawing Sheets
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LIGHT-ACTIVATED COMPOUNDS

FIG. 2 includes images showing an ellipsoid plot (at 50%
probability) of2 (left) and a capped stick overlay of2 (right).
Both biquinoline ligands have a 20° bend from the ideal
octahedral plane, where the N(3)-N( 4) biquinoline has a 12°
twist about the C---C bond between the two quinolones and
the N(1)-N(2) biquinoline does not.
FIG. 3 includes a reaction scheme showing the photosubstitution reaction of 2 in H 2 0, and further includes charts
showing the associated UV/Vis absorption spectra at different
time points in the reaction under blue light, where the inset
shows the kinetic fit for the reaction.
FIGS. 4A to 4E includes images showing agarose gel electrophoresis for the dose response ofl (left) and 2 (right) with
40 flg/mL pUC19 plasmid in the (Figure A) dark and after
irradiation with (FIG. 4B) blue (>400 nm), (FIG. 4C) green
(>450 nm), (FIG. 4D) red (>600 nm), and (FIG. 4E) near-IR
(>650nm)light. Lane 1: DNA ladder; Lane2: EcoRI; Lane3:
Cu(OP) 2 ; Lane 4:0 f.LM; Lane 5: 15 f.LM; Lane 6: 30 f.LM; Lane
7: 60 f.LM; Lane 8: 125 f.LM; Lane 9: 250 f.LM; Lane 10: 500 f.LM;
Lane 11: 1,000 f.LM; Lane 12: DNA Ladder.
FIG. 5 includes charts showing the UVNis absorption of 4
following photoejection in buffer (10 mM phosphate buffer,
pH 7 .5), where the inset shows the photoejection kinetics.
FIGS. 6A to 6D includes images showing agarose gels
electrophoresis for 40 flg/mL pUC19 plasmid (1 0 mM phosphate buffer, pH 7.5)with(FIG. 6A) 3, (FIG. 6B) 4, and(FIG.
6C) 5, where Lanes 1 and 12: DNA molecular weight standard, Lane2: linearpUC19, Lane3: relaxed circle (Cu(phen) 2
reaction with pUC19), Lanes 4-11: 0, 7 .5, 15, 30, 60, 120,
240, and 500 f.LM compound; and further includes agarose gel
electrophoresis showing (FIG. 6D) Lanes 1 and 14: DNA
molecular weight standard, Lane 2: pUC19, Lane3: pUC19+
40 mM GSH. Cisplatin (30 f.LM, lanes 4-8) and compound 4
(30 f.LM, lanes 9-13) were dosed with GSH: lanes 4-8 and
9-13: 0.01, 0.1, 1, 10, 40 mM GSH.
FIGS. 7A to 7D includes charts showing the cytotoxicity
dose responses of metal complexes in HL60 cells for (FIG.
7A)cisplatin, (FIG. 7B)3, (FIG. 7C) 4, and(FIG. 7D) 5. Dark
conditions (circles); irradiated samples, 3 min>450 nm light
(squares). (n=3).
FIGS. SA to SB includes charts showing the cytotoxicity
dose responses in A549 tumor spheroids for (FIG. SA) compound 4 (dark conditions, circles; irradiated samples, 3
min>450 nm light, squares), and (FIG. SB) cisplatin (dark
conditions, squares; ALA, irradiated samples, 3 min>450 nm
light, circles). (n=3.)
FIGS. 9A and 9B include (FIG. 9A) a scheme for the
selective photoejection of dmdppz from 8 with A.>400 nm
light, and (FIG. 9B) a chart ofUVNis monitoring of photoejection in the presence of CT DNA (1 0: 1 nucleotide: 8),
where the kinetic fit for the photochemical reaction is shown
in the inset.
FIG. 10 includes images showing the crystal structure of
racemic (left) compound 7 and (right) compound 8, where
ellipsoids are drawn to 50% probability and hydrogen atoms
are excluded for clarity.
FIG. 11 includes an illustration showing a Jablonski diagram for compound 8 (BS=Bright State; DS=Dark State; NR
Decay=nonradiative decay).
FIGS. 12A to 12D includes images showing agarose gel
electrophoresis of 40 flg/ml pUC19 with increasing concentrations of (FIG. 12A) 9 and (FIG. 12B) 10 in the dark or
irradiated (lanes 1 and 12, DNA molecular weight standard;
lane 2, linear (reaction with EcoR1); lane 3, relaxed circle
(reaction with Cu(phen) 2 ); lanes 4-11, 0, 7 .5, 15, 30, 60, 120,
240, and 500 f.LM compound); and further includes charts

RELATED APPLICATIONS
This applications claims priority from U.S. Provisional
Application Ser. No. 61/799,678, filed Mar. 15, 2013, the
entire disclosure of which is incorporated herein by this reference.
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TECHNICAL FIELD

10

The presently-disclosed subject matter relates to light-activated compounds. In particular, presently-disclosed subject
matter relates to light -activated ruthenium compounds as well
as methods for using the same.

15

INTRODUCTION
Photoactivation is an elegant method to convert non-toxic
prodrugs to active cytotoxic species in a spatially and temporally controlled mauner. Photoactivation provides a mechanism to discriminate between malignant tissues of tumors and
the surrounding healthy tissues, potentially reducing the
dose-limiting side effects incurred with standard chemotherapies. Photodynamic therapy (PDT) uses this light-targeted
approach, and has been successfully applied in the treatment
of various cancers, notably of the lung, esophagus, and skin.
PDT commonly requires a photosensitizer such as a porphyrin to generate singlet oxygen eo2), which is the actual
toxic moiety. However, this requirement for oxygen has limited the utility of PDT, due to the hypoxic nature of many
tumors. Known porphyrin-type organic photo sensitizers used
in PDT also have other poor chemical characteristics, and
suffer from photobleaching, poor solubility, and retention in
tissues, causing protracted photosensitivity.
In light of these drawbacks, several groups are investigating photoactive metal compounds (complexes) as alternative
PDT agents. For instance, ruthenium polypyridyl compounds
have tunable absorption properties, and can induce 1 0 2 -mediated DNA photocleavage when exposed to UV to visible
light. Some ruthenium agents also can act via oxygen-independent mechanisms, allowing for activity in hypoxic tissues.
However, unlike organic PDT sensitizers, known metal compounds are not activated, and therefore are not cytotoxic,
within the "therapeutic window" for PDT, which includes red
and near infrared (IR) light from 600-1100 urn.
Hence, there remains a need for improved PDT agents, and
specifically compounds that are thermally inert and that can
be triggered by low energy, visible light to generate toxic
species for use as, for example, chemotherapeutics. There are
remains a need for agents that are easy to synthesize, have a
flexible design that can be modified without unduly compromising efficacy, and retain activity in the presence ofbiological reducing agents, such as glutathione. Further still, there
remains a need for agents having structural motifs that are
distinct from those of known agents (e.g., square planar platinum compounds) so that they may retain efficacy in subjects
that have otherwise developed resistance to known drugs,
such as cisplatin and its analogues.
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BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 includes structures showing Ru(II) complexes, and
further includes charts showing the UV/Vis absorption spectra of 1 (black) and 2 (gray), where the inset shows the
absorption in a region of the PDT window (600 nm-900 nm).
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showing the cytotoxicity dose response of (FIG. 12C) 1 and
(FIG.12D) 10 in the dark (open squares) or irradiated (closed
circles).
FIGS. 13A and 13 B includes apoptome micrographs showing subcellular localization of 9 and 10 at 8 hours, where
(FIG. 13A) Mitotracker Green FM was used to image mitochondria, and (FIG. 13B) Lysotracker Green DND-26 was
used to image lysosomes.
FIGS. 14A to 14D includes charts showing mitochondrial
potential and cell viability ofHL60 cells as a function of time
for (FIG. 14A) 9, dark, (FIG. 14B) 9, irradiated; (FIG. 14C)
10, dark; (FIG.14D) 10, irradiated. TMRE was used to quantify membrane potential; values are relative to a no-compound control value of 100.
FIGS. 15A and 15B include images of (FIG. 15A) a Westem blot analysis of cleaved PARP, Caspase 3, and ProCaspase 3, where GAPDH was used as a loading control, and
(FIG. 15B) agarose gel electrophoresis of genomic DNA
harvested from HL60 cells after treatment with various agents
(Lanes 1 and 9; ladder; 2, no compound control; 3, 10%
EtOH, 24 hours (necrosis control); 4, cisplatin, 24 hours
(apoptosis control); 5, 9+hv, 8 hours; 6, 9-hv, 8 hours; 7,
10+hv, 24 hours; 8, 10-hv, 24 hours).

C(O)R, S, S(R), 0, O(R), and P, wherein R is selected from H,
OH, alkyl, and aryl, and m is -6 to +6.
As used herein, the term "substituted" is contemplated to
refer to compounds that have been modified with any and all
permissible substituents. In a broad aspect, the permissible
substituents include acyclic and cyclic, branched and
unbranched, carbocyclic and heterocyclic, and aromatic and
nonaromatic substituents of organic compounds. Illustrative
substituents include, for example, those described below. The
permissible substituents can be one or more and the same or
different for appropriate compounds. For example, in some
embodiments the compounds that comprise polypyridyl
ligands that have been substituted with alkyl substituents
and/or any other permissible substituents described herein. In
certain embodiments the present compounds are substituted
with a substituent that can induced strain in the compounds.
This disclosure is not intended to be limited in any manner by
the permissible substituents of the present compounds.
Also, the terms "substitution" or "substituted with" include
the implicit proviso that such substitution is in accordance
with permitted valence of the substituted atom and the substituent, and that the substitution results in a stable compound, e.g., a compound that does not spontaneously undergo
transformation such as by rearrangement, cyclization, elimination, etc.
In defining various terms, "A 1 ,""A2 ,""A3 ," and "A4 ", or the
like, are used herein as generic symbols to represent various
specific substituents. These symbols can be any substituent,
not limited to those disclosed herein, and when they are
defined to be certain substituents in one instance, they can, in
another instance, be defined as some other substituents.
The term "alkyl" as used herein is a branched or
unbranched saturated hydrocarbon group of 1 to 24 carbon
atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl,
isobutyl, s-butyl, t-butyl, n-pentyl, isopentyl, s-pentyl, neopentyl, hexyl, heptyl, octyl, nonyl, decyl, dodecyl, tetradecyl,
hexadecyl, eicosyl, tetracosyl, and the like. The alkyl group
can be cyclic or acyclic. The alkyl group can be branched or
unbranched. The alkyl group can also be substitutedorunsubstituted. For example, the alkyl group can be substituted with
one or more groups including, but not limited to, optionally
substituted alkyl, cycloalkyl, alkoxy, amino, ether, halide,
hydroxy, nitro, silyl, sulfo-oxo, or thiol, as described herein.
A "lower alkyl" group is an alkyl group containing from one
to six (e.g., from one to four) carbon atoms.
Throughout the specification "alkyl" is generally used to
refer to both unsubstituted alkyl groups and substituted
alkyl groups; however, substituted alkyl groups are also specifically referred to herein by identifYing the specific substituent(s) on the alkyl group. For example, the term "halogenated
alkyl" specifically refers to an alkyl group that is substituted
with one or more halide, e.g., fluorine, chlorine, bromine, or
iodine. The term "alkoxyalkyl" specifically refers to an alkyl
group that is substituted with one or more alkoxy groups, as
described below. The term "alkylamino" specifically refers to
an alkyl group that is substituted with one or more amino
groups, as described below, and the like. When "alkyl" is used
in one instance and a specific term such as "alkylalcohol" is
used in another, it is not meant to imply that the term "alkyl"
does not also refer to specific terms such as "alkylalcohol"
and the like.
This practice is also used for other groups described herein.
That is, while a term such as "cycloalkyl" refers to both
unsubstituted and substituted cycloalkyl moieties, the substituted moieties can, in addition, be specifically identified
herein; for example, a particular substituted cycloalkyl can be
referred to as, e.g., an "alkylcycloalkyl." Similarly, a substi-
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DESCRIPTION OF EXEMPLARY
EMBODIMENTS
The details of one or more embodiments of the presentlydisclosed subject matter are set forth in this document. Modifications to embodiments described in this document, and
other embodiments, will be evident to those of ordinary skill
in the art after a study of the information provided in this
document. The information provided in this document, and
particularly the specific details of the described exemplary
embodiments, is provided primarily for clearness of understanding and no unnecessary limitations are to be understood
therefrom. In case of conflict, the specification of this document, including definitions, will control.
The presently-disclosed subject matter includes light-activated metal compounds, and in particular, certain embodiments include ruthenium (Ru) compounds. In some embodiments of ruthenium compounds comprise a ruthenium metal
core and one or more ligands, wherein one or more ligands are
released from the ruthenium metal center when the compound is exposed to light. As used herein, the terms "compound," "complex," and the like are used interchangeably to
refer to embodiments of light-activated metal substances.
More specifically, the presently-disclosed subject matter
includes compounds having structures represented by the
following formula:

+1-m
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wherein Xu X 2 , and X 3 , the same or different from one
another, are selected from bidentate nitrogen heterocycles,
metallocycles, or a combination thereof, and are optionally
substituted with one or more of alkyl, aryl, amine, C(O),
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tuted alkoxy can be specifically referred to as, e.g., a "halogenated alkoxy," a particular substituted alkenyl can be, e.g.,
an "alkenylalcohol," and the like. Again, the practice of using
a general term, such as "cycloalkyl," and a specific term, such
as "alkylcycloalkyl," is not meant to imply that the general
term does not also include the specific term.
The term "cycloalkyl" as used herein is a non-aromatic
carbon-based ring composed of at least three carbon atoms.
Examples of cycloalkyl groups include, but are not limited to,
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, norbornyl,
and the like. The term "heterocycloalkyl" is a type of
cycloalkyl group as defined above, and is included within the
meaning of the term "cycloalkyl," where at least one of the
carbon atoms of the ring is replaced with a heteroatom such
as, but not limited to, nitrogen, oxygen, sulfur, or phosphorus.
The cycloalkyl group and heterocycloalkyl group can be substituted or unsubstituted. The cycloalkyl group and heterocycloalkyl group can be substituted with one or more groups
including, but not limited to, optionally substituted alkyl,
cycloalkyl, alkoxy, amino, ether, halide, hydroxy, nitro, silyl,
sulfo-oxo, or thiol as described herein.
In this regard, the term "heterocycle," as used herein refers
to single and multi-cyclic aromatic or non-aromatic ring systems in which at least one of the ring members is other than
carbon. Heterocycle includes pyridine, pyrimidine, furan,
thiophene, pyrrole, isoxazole, isothiazole, pyrazole, oxazole,
thiazole, imidazole, oxazole, including, 1,2,3-oxadiazole,
1,2,5-oxadiazole and 1,3,4-oxadiazole, thiadiazole, including, 1,2,3-thiadiazole, 1,2,5-thiadiazole, and 1,3,4-thiadiazole, triazole, including, 1,2,3-triazole, 1,3,4-triazole, tetrazole, including 1,2,3,4-tetrazole and 1,2,4,5-tetrazole,
pyridine, pyridazine, pyrimidine, pyrazine, triazine, including 1,2,4-triazine and 1,3,5-triazine, tetrazine, including 1,2,
4,5-tetrazine, pyrrolidine, piperidine, piperazine, morpholine, azetidine, tetrahydropyran, tetrahydrofuran, dioxane,
and the like.
The term "aryl" as used herein is a group that contains any
carbon-based aromatic group including, but not limited to,
benzene, naphthalene, phenyl, biphenyl, phenoxybenzene,
and the like. The term "aryl" also includes "heteroaryl,"
which is defined as a group that contains an aromatic group
that has at least one heteroatom incorporated within the ring
of the aromatic group. Examples ofheteroatoms include, but
are not limited to, nitrogen, oxygen, sulfur, and phosphorus.
Likewise, the term "non-heteroaryl," which is also included
in the term "aryl," defines a group that contains an aromatic
group that does not contain a heteroatom. The aryl group can
be substituted or unsubstituted. The aryl group can be substituted with one or more groups including, but not limited to,
optionally substituted alkyl, cycloalkyl, alkoxy, alkenyl,
cycloalkenyl, alkynyl, cycloalkynyl, aryl, heteroaryl, aldehyde, amino, carboxylic acid, ester, ether, halide, hydroxy,
ketone, azide, nitro, silyl, sulfo-oxo, or thiol as described
herein. The term "biaryl" is a specific type of aryl group and
is included in the definition of"aryl." Biaryl refers to two aryl
groups that are bound together via a fused ring structure, as in
naphthalene, or are attached via one or more carbon-carbon
bonds, as in biphenyl.
The term "aldehyde" as used herein is represented by a
formula ---C(O)H. Throughout this specification "C(O)" is a
short hand notation for a carbonyl group, i.e., C=O.
The terms "amine" or "amino" as used herein are represented by a formula NA 1 A 2 A 3 , where A\ A 2 , andA 3 can be,
independently, hydrogen or optionally substituted alkyl,
cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl,
aryl, or heteroaryl group as described herein.

Reference to any of the compounds described here also
includes reference to any pharmaceutically acceptable
derivative thereof, regardless of whether this is expressly
stated for each compound. The term "derivative" is used
herein to refer to a compound having a structure derived from
the structure of a parent compound (e.g., a compounds disclosed herein) and whose structure is sufficiently similar to
those disclosed herein and based upon that similarity, would
be expected by one skilled in the art to exhibit the same or
similar activities and utilities as the claimed compounds, or to
induce, as a precursor, the same or similar activities and
utilities as the claimed compounds. Exemplary derivatives
include salts, esters, amides, salts of esters or amides, and
N -oxides of a parent compound. The term "pharmaceutically
acceptable" describes a material that is not biologically or
otherwise undesirable, i.e., without causing an unacceptable
level of undesirable biological effects or interacting in a deleterious marmer.
In some embodiments at least one of Xu X 2 , and X 3 (i.e.,
ligands) are released when the compound is exposed to light.
In this regard, in some embodiments the compounds comprise at least one ligand that is inherently strain-inducing
and/or a ligand that includes a strain-inducing group (substituent). The term "strain-inducing group" generally refers to
the general characteristic of a group that can create a steric
clash in a compound. In specific embodiments "strain-inducing" refers to the characteristic of a compound having bond
lengths and/or bond angles that deviate by 5% or more relative to the ideal bond lengths and/or bond angles determined
by VSEPR theory. Such determinations can be made by analyzing the crystal structure of a compound, for example.
Thus, in some embodiments at least one of Xu X 2 , and X 3
can be a strain-inducing ligand that produces a steric clash in
the compound, which can facilitate release of the ligands
upon being exposed to certain light. In some instances the
term strain inducing is used to refer to a group or substituent
that gives rise to strain-inducing properties. For example, a
ligand can be substituted with one or more strain-inducing
groups that impart a strain-inducing characteristic to the
ligand. In specific embodiments the strain-inducing group is
located in a ligand at a position ortho to the chelating nitrogen
of a bidentate nitrogen heterocycle.
Some exemplary ligands are represented by the formula:
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wherein each R 1 is independently selected from H, amine,
amide, alkyl, aryl, SR4 , PR4 , 0, OR4 , halogen, or S03 H, R4
being H, alkyl, or aryl, or wherein R 1 and R3 taken together
with the carbon atoms to which they are bonded, form a
substituted or unsubstituted ring containing about 4-6 ring
carbon atoms that optionally include one or more N, each R 2
isH, amine, amide, alkyl, aryl, SR4 , PR4 , 0, OR4 , halogen, or
S03 H, each R3 is independently selected from H, amine,
amide, alkyl, aryl, SR4 , PR4 , 0, OR4 , halogen, or S0 3 H, or
wherein R3 and R4 taken together with the carbon atoms to
which they are bonded, form a substituted or unsubstituted
ring containing about 4-6 ring carbon atoms that optionally
include one or more N, and each R4 isH, amine, amide, alkyl,
aryl, SR4 , PR4 , 0, OR4 , halogen, or S0 3 H.
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In some embodiments exemplary ligands are represented
by the formula:
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wherein each R 1 is independently selected from H, amine,
amide, alkyl, aryl, SR4 , PR4 , 0, OR4 , halogen, or S03 H, R4
being H, alkyl, or aryl, or wherein R 1 and R3 taken together
with the carbon atoms to which they are bonded, form a
substituted or unsubstituted ring containing about 4-6 ring
carbon atoms that optionally include one or more N, and each
R 2 isH, amine, amide, alkyl, aryl, SR4 , PR4 , 0, OR4 , halogen,
or S0 3 H.
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by the formula:
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A non-limiting list of exemplary ligands, both strain-inducing and not, that can be incorporated in compounds of the
presently-disclosed subject matter also include those represented by the following structures:
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o=Q. d-b
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tBu

wherein R 1 and R 2 , the same or different from one another, are
any group other than H. In some embodiments the straininducing group (e.g., R 1 and R 2 ) is an alkyl, such as a methyl
group. Other examples of strain-inducing groups include, but
are not limited to, cycloalkyl, phenyl, aryl, and heteroatom
(e.g., N, 0, S, P, Cl, Br, I, etc.) substituents. The ligands can be
selected from the group consisting of, but are not limited to,
2,2'-bipyridyl, dipyrido[3,2-f:2',3'-h]-quinoxaline, 1,10phenanthroline, hydroxyquinoline, and the like.
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In some embodiments the compound comprises a structure
according to at least one of the following formula:
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More specifically, light can refer to electromagnetic radia-continued
tion having a wavelength of about 350 nm to about 500 nm. In
other embodiments light includes energy having a wavelength of about 500 nm to about 1000 nm. In specific embodi5 ments light can refer to energy having a wavelength of about
300 nm, about 350 nm, about 450 nm, about 500 nm, about
550 nm, about 600 nm, about 650 nm, about 700 nm, about
750 nm, about 800 nm, about 850 nm, about 900 nm, about
950 nm, or about 1000 nm. In other specific embodiments
10 light can refer to energy having a wavelength greater than
about 300 nm, greater than about 350 nm, greater than about
450 nm, greater than about 500 nm, greater than about 550
nm, greater than about 600 nm, greater than about 650 nm,
greater than about 700 nm, greater than about 7 50 nm, greater
15 than about 800 nm, greater than about 850 nm, greater than
about 900 nm, or greater than about 950 nm.
Still further, some embodiments of compounds also comprise a targeting agent and/or a therapeutic agent. Folate,
estrogen, and eroltinib are examples of a targeting agent that
20 can be used in embodiments of the presently-disclosed compounds. Those of ordinary skill will appreciate other small
molecule targeting agents that can be incorporated into the
present compounds. Additionally, hydroxyquinoline is an
example of a therapeutic agent that can be used in embodi25 ments of the presently-disclosed compounds. In some
embodiments the photo-releasable ligands of the embodied
compounds can be a targeting agent and/or a therapeutic
agent.
The presently-disclosed compounds can further comprise
30 an overall charge. In some embodiments the overall charge is
-6 to +6. The overall charge can depend on the ligands incorporated into embodied compounds. For example, in some
embodiments ligands comprising carboxylic acid and/or sulfonic acid result in compounds that have negative (e.g., -2)
35 overall charges at physiological pH. In specific embodiments
the present compounds comprise an overall charge of -6, -5,
-4, -3, -2, -1, neutral charge,+ 1, +2, +3, +4, +5, or +6. Those
of ordinary skill will appreciate that depending on the ligands
of the present compounds, the overall charge may also be less
40 than about -6 or greater than about +6.
The presently-disclosed subject matter further includes
pharmaceutical compositions of the compounds as disclosed
herein, and further includes a pharmaceutically-acceptable
carrier. In this regard, the term "pharmaceutically acceptable
45 carrier" refers to sterile aqueous or nonaqueous solutions,
dispersions, suspensions or emulsions, as well as sterile powders for reconstitution into sterile injectable solutions or dispersions just prior to use. Proper fluidity can be maintained,
for example, by the use of coating materials such as lecithin,
so by the maintenance of the required particle size in the case of
dispersions and by the use of surfactants. These compositions
can also contain adjuvants such as preservatives, wetting
In some embodiments the light-activated properties of the
agents, emulsifying agents and dispersing agents. Prevention
compounds can be tuned based on the selection of ligands
of the action of microorganisms can be ensured by the incluand/or substituents, and the compounds can be tuned to be
55 sian of various antibacterial and antifungal agents such as
photo-activated (i.e., release ligands) when exposed to light
paraben, chlorobutanol, phenol, sorbic acid and the like. It
having particular wavelengths. In this regard, the term "light"
can also be desirable to include isotonic agents such as sugars,
is used herein to refer to any electromagnetic radiation that
sodium chloride and the like. Prolonged absorption of the
can activate a compound. In some embodiments light
injectable pharmaceutical form can be brought about by the
includes ultraviolet light, visible light, near infrared light 60 inclusion of agents, such as aluminum mono stearate and gela(NIR), or infrared light (IR). Compounds activated by relatin, which delay absorption. Injectable depot forms are made
tively long wavelength light may be particularly well suited
by forming microencapsule matrices of the drug in biodefor targeting tumors and the like that are deep in tissues, since
gradable polymers such as polylactide-polyglycolide, poly
light generally penetrates deeper into tissues as the wave(orthoesters) and poly(anhydrides). Depending upon the ratio
length increases. Some embodiments of compounds have the 65 of drug to polymer and the nature of the particular polymer
surprising and unexpected advantage of being photo-actiemployed, the rate of drug release can be controlled. Depot
vated by light having wavelengths greater than 500 nm.
injectable formulations are also prepared by entrapping the

US 9,290,528 Bl

15

16

drug in liposomes or microemulsions which are compatible
with body tissues. The injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining
filter or by incorporating sterilizing agents in the form of
sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable media just
prior to use. Suitable inert carriers can include sugars such as
lactose.
Suitable formulations include aqueous and non-aqueous
sterile injection solutions that can contain antioxidants, buffers, bacteriostats, bactericidal antibiotics and solutes that render the formulation isotonic with the bodily fluids of the
intended recipient; and aqueous and non-aqueous sterile suspensions, which can include suspending agents and thickening agents.
The compositions can take such forms as suspensions,
solutions or emulsions in oily or aqueous vehicles, and can
contain formulatory agents such as suspending, stabilizing
and/or dispersing agents. Alternatively, the active ingredient
can be in powder form for constitution with a suitable vehicle,
e.g., sterile pyrogen-free water, before use.
The formulations can be presented in unit-dose or multidose containers, for example sealed ampoules and vials, and
can be stored in a frozen or freeze-dried (lyophilized) condition requiring only the addition of sterile liquid carrier immediately prior to use.
For oral administration, the compositions can take the form
of, for example, tablets or capsules prepared by a conventional technique with pharmaceutically acceptable excipients
such as binding agents (e.g., pregelatinized maize starch,
polyvinylpyrrolidone or hydroxypropyl methylcellulose);
fillers (e.g., lactose, microcrystalline cellulose or calcium
hydrogen phosphate); lubricants (e.g., magnesium stearate,
talc or silica); disintegrants (e.g., potato starch or sodium
starch glycollate ); or wetting agents (e.g., sodium Iaury! suiphate). The tablets can be coated by methods known in the art.
Liquid preparations for oral administration can take the
form of, for example, solutions, syrups or suspensions, or
they can be presented as a dry product for constitution with
water or other suitable vehicle before use. Such liquid preparations can be prepared by conventional techniques with
pharmaceutically acceptable additives such as suspending
agents (e.g., sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (e.g. lecithin or acacia);
non-aqueous vehicles (e.g., almond oil, oily esters, ethyl alcohoi or fractionated vegetable oils); and preservatives (e.g.,
methyl or propyl-p-hydroxybenzoates or sorbic acid). The
preparations can also contain buffer salts, flavoring, coloring
and sweetening agents as appropriate. Preparations for oral
administration can be suitably formulated to give controlled
release of the active compound. For buccal administration the
compositions can take the form of tablets or lozenges formulated in conventional manner.
The compounds can also be formulated as a preparation for
implantation or injection. Thus, for example, the compounds
can be formulated with suitable polymeric or hydrophobic
materials (e.g., as an emulsion in an acceptable oil) or ion
exchange resins, or as sparingly soluble derivatives (e.g., as a
sparingly soluble salt).
The compounds can also be formulated in rectal compositions (e.g., suppositories or retention enemas containing conventional suppository bases such as cocoa butter or other
glycerides), creams or lotions, or transdermal patches.
The presently-disclosed subject matter further includes a
kit that can include a compound/or pharmaceutical composition as described herein, packaged together with a device
useful for administration of the compound or composition. As

will be recognized by those or ordinary skill in the art, the
appropriate administration aiding device will depend on the
formulation of the compound or composition that is selected
and/or the desired administration site. For example, if the
formulation of the compound or composition is appropriate
for injection in a subject, the device could be a syringe. For
another example, if the desired administration site is cell
culture media, the device could be a sterile pipette.
In some embodiments a kit can comprise one of the present
compounds and/or pharmaceutical compositions thereof as
well as a device for activating the compound or pharmaceutical composition. In some embodiments the device is a lightemitting device that emits light having at least a wavelength
that can activate the compound or pharmaceutical composition. Accordingly, the device can be capable of emitting light
having at least a wavelength of 500 nm or more, and in some
instances a wavelength in a range of about 500 nm to about
1100 nm. In certain embodiments the device is a laser.
Still further, the presently-disclosed subject matter
includes a method for treating cancer. In some embodiments
the method comprises administering a compound, including
one of the compounds described herein, to a subject in need
thereof, and then exposing a site of the subject to light after
the compound has been administered. As described above, the
light in some embodiments can be a light having a wavelength
of about 350 nm to about 1000 nm.
The term "administering" refers to any method of providing a compound and/or pharmaceutical composition thereof
to a subject. Such methods are well known to those skilled in
the art and include, but are not limited to, oral administration,
transdermal administration, administration by inhalation,
nasal administration, topical administration, intravaginal
administration, ophthalmic administration, intraaural administration, intracerebral administration, rectal administration,
and parenteral administration, including injectable such as
intravenous administration, intra-arterial administration,
intramuscular administration, and subcutaneous administration. Administration can be continuous or intermittent. In
various aspects, a preparation can be administered therapeutically; that is, administered to treat an existing disease or
condition (e.g., cancer, tumors, etc.). In further various
aspects, a preparation can be administered prophylactically;
that is, administered for prevention of a disease or condition.
In some embodiments a subject will be administered an
effective amount of the compound. In this respect, the term
"effective amount" refers to an amount that is sufficient to
achieve the desired result or to have an effect on an undesired
condition. For example, a "therapeutically effective amount"
refers to an amount that is sufficient to achieve the desired
therapeutic result or to have an effect on undesired symptoms,
but is generally insufficient to cause adverse side effects. The
specific therapeutically effective dose level for any particular
patient will depend upon a variety of factors including the
disorder being treated and the severity of the disorder; the
specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration; the route of administration; the rate of excretion of the
specific compound employed; the duration of the treatment;
drugs used in combination or coincidental with the specific
compound employed and like factors well known in the medical arts. For example, it is well within the skill of the art to
start doses of a compound at levels lower than those required
to achieve the desired therapeutic effect and to gradually
increase the dosage until the desired effect is achieved. If
desired, the effective daily dose can be divided into multiple
doses for purposes of administration. Consequently, single
dose compositions can contain such amounts or submultiples
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thereof to make up the daily dose. The dosage can be adjusted
by the individual physician in the event of any contraindications. Dosage can vary, and can be administered in one or
more dose administrations daily, for one or several days.
Guidance can be found in the literature for appropriate dosages for given classes of pharmaceutical products. In further
various aspects, a preparation can be administered in a "prophylactically effective amount"; that is, an amount effective
for prevention of a disease or condition.
Additionally, the terms "subject" or "subject in need
thereof' refer to a target of administration, which optionally
displays symptoms related to a particular disease, pathological condition, disorder, or the like. The subject of the herein
disclosed methods can be a vertebrate, such as a mammal, a
fish, a bird, a reptile, or an amphibian. Thus, the subject of the
herein disclosed methods can be a human, non-human primate, horse, pig, rabbit, dog, sheep, goat, cow, cat, guinea pig
or rodent. The term does not denote a particular age or sex.
Thus, adult and newborn subjects, as well as fetuses, whether
male or female, are intended to be covered. A patient refers to
a subject afflicted with a disease or disorder. The term "subject" includes human and veterinary subjects.
In some embodiments the subject in need thereof will be
suffering or will have been diagnosed with one or more neoplastic or hyperproliferative diseases, disorders, pathologies,
or conditions. Thus, a site to be exposed in a subject may be
in close proximity or at the location of such a disease, condition, etc. (e.g., tumor). Examples of such diseases, conditions,
and the like include, but are not limited to, neoplasms (cancers or tumors) located in the colon, abdomen, bone, breast,
digestive system, esophagus, liver, pancreas, peritoneum,
endocrine glands (adrenal, parathyroid, pituitary, testicles,
ovaries, cervix, thymus, thyroid), eye, head and neck, nervous
(central and peripheral), lymphatic system, pelvis, skin, soft
tissue, spleen, thoracic areas, bladder, and urogenital system.
Other cancers include follicular lymphomas, carcinomas
with p53 mutations, and hormone-dependent tumors, including, but not limited to colon cancer, cardiac tumors, pancreatic cancer, melanoma, retinoblastoma, glioblastoma, lung
cancer, intestinal cancer, testicular cancer, stomach cancer,
neuroblastoma, myxoma, myoma, lymphoma, endothelioma,
osteoblastoma, osteoclastoma, osteosarcoma, chondrosarcoma, adenoma, breast cancer, prostate cancer, Kaposi's sarcoma and ovarian cancer, or metastases thereof.
A subject may also be in need thereof because they have
acquired diseases or conditions associated with abnormal and
increased cell survival such as, but are not limited to, progression and/or metastases of malignancies and related disorders
such as leukemia (including acute leukemias (e.g., acute lymphocytic leukemia, acute myelocytic leukemia, including
myeloblastic, promyelocytic, myelomonocytic, monocytic,
and erythroleukemia) and chronic leukemias (e.g., chronic
myelocytic (granulocytic) leukemia and chronic lymphocytic
leukemia)), polycythemia vera, lymphomas (e.g., Hodgkin's
disease and non-Hodgkin's disease), multiple myeloma,
Waldenstrom' s macroglobulinemia, heavy chain disease, and
solid tumors including, but not limited to, sarcomas and carcinomas such as fibrosarcoma, myxosarcoma, liposarcoma,
chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's
tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma,
adenocarcinoma, sweat gland carcinoma, sebaceous gland
carcinoma, papillary carcinoma, papillary adenocarcinomas,
cystadenocarcinoma, medullary carcinoma, bronchogenic

carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma,
Wilm's tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma,
ependymoma,
pinealoma,
hemangioblastoma, acoustic neuroma, oligodendroglioma,
menangioma, melanoma, neuroblastoma, and retinoblastoma. The conditions, diseases, and the like described above,
as well as those that will be apparent to those of ordinary skill
in the art, are collectively referred to as "cancer" herein.
The terms "treatment" or "treating" refer to the medical
management of a subject with the intent to cure, ameliorate,
stabilize, or prevent a disease, pathological condition, or disorder. This term includes active treatment, that is, treatment
directed specifically toward the improvement of a disease,
pathological condition, or disorder, and also includes causal
treatment, that is, treatment directed toward removal of the
cause of the associated disease, pathological condition, or
disorder. In addition, this term includes palliative treatment,
that is, treatment designed for the relief of symptoms rather
than the curing of the disease, pathological condition, or
disorder; preventative treatment, that is, treatment directed to
minimizing or partially or completely inhibiting the development of the associated disease, pathological condition, or
disorder; and supportive treatment, that is, treatment
employed to supplement another specific therapy directed
toward the improvement of the associated disease, pathological condition, or disorder.
With regard to the step of exposing a site, the method of
exposing can be modified to meet the needs of a particular
situation. Accordingly, the light can be sunlight, photo-optic
light, or laser light, and thus the light can be ultraviolet light,
visible light, near infrared light, or infrared light, for example.
The light can be exposed from a laser light source, a tungsten
light source, a photooptic light source, and the like. Light can
also be exposed in at relatively specific sites, and therefore
can be exposed by the use of laser technology, fibers, probes,
tubes, and the like. Such probes, fibers, or tubes can be
directly inserted, for example, into a body cavity or opening
of a subject, or under or through the skin of a subject, to
expose the compounds that have been administered to light.
It will be appreciated that embodiments of the presentlydisclosed subject matter resolve the unmet needs in the art,
including specific embodiments of strained Ru(II) polypyridyl complexes that utilize the steric clash of their ligands to
promote visible light mediated ligand expulsion. While unreactive in the dark, these exemplary compounds are transformed upon light activation into potent cytotoxic species. As
potential PDT agents, these compounds offer key advantages,
including ease of synthesis, high solubility, low dark toxicities, and resistance to inactivation by thiol reagents. In certain
embodiments, the DNA damaging mechanism appears to
mimic the activity of cisplatin, which would make them
potentially amenable to a variety of cancer types, and also can
have greater potency than cisplatin.
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EXAMPLE
The presently-disclosed subject matter is further illustrated
by the following specific but non-limiting example. The
example may include compilations of data that are representative of data gathered at various times during the course of
development and experimentation related to the presentlydisclosed subject matter.
Example 1
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In this Example two heteroleptic complexes were synthesized containing one and two biquinoline (biq) ligands, and
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one or two smaller, non -strained 1, 10-phenanthroline (phen)
ligands, as shown in FIG. 1. The synthesis and purification
was performed under low ambient light in order to avoid
photo-decomposition. The addition of the biq ligands resulted
in bathochromic shifts in the absorption spectra, as compared
to Ru(phen) 3 , a prototypical Ru(II) polypyridyl complex with
a "-max=450 nm for the low energy MLCT absorption. As
shown in FIG. 1, addition of one biquinoline ligand in 1 shifts
the MLCT to lower energies, with "-max=525 nm. Incorporation of two biquinoline ligands further shifts the "-max to 550
nm for 2. Expansion of the region from 600-900 nm shows
that there is some absorption at 700 nm for 1, while 2 is able
to absorb light up to goo nm.
Analysis of the crystal structures for the biquinoline complexes provided a means to compare the extent of distortion in
the ground state structures. The deformation of the octahedral
geometry was manifest in lengthening of the bonds between
the metal and the ligand as well as twisting of the ligands
(FIG. 2). In comparison with Ru(phen) 3 , an undistorted octahedral complex with average Ru-N bond lengths of2.064 A,
compound 2 was slightly distorted with the Ru-N bonds
lengthened to 2.0g-2.10A, as shown in FIG. 2 and Table 1. In
compound 1, one of the phenanthroline ligands maintains an
average length similar to that ofRu(phen) 3 at about 2.060 A,
while the other two ligands' Ru-N bonds are lengthened to
an average of 2.11 and 2.09 A. The biquinoline in 1 was
twisted by 5° about the C-C bond between the two quinoline
systems. In contrast, the two biquinoline ligands showed different distortions in compound 2, with biq(2) exhibiting a
12.1(4°) twist, while biq(1) has a 2.7(4°) rotation. The
biquinolines are also bent out of the normal plane by appro ximately 20° in both complexes, while the phenanthroline
ligands stay in the plane. This bend out of plane tips the
biquinoline toward the phenanthroline ligand for 2, creating a
7° increase in the angle between the biquinoline ligands, as
well as an go and 10° compression in the biquinoline-phenanthroline angle. In contrast, the biquinoline ligand in compound 1 pushes the two phenanthroline ligands toward each
other by go. In both structures the biquinoline ligands maximize the space around them, which induces the distortion in
complexes 1 and 2.

well with the absorption spectra, with rapid reaction observed
with blue and green light, while slower ejection kinetics
occurred with red and near-IR light. The most rapid ejection
was observed with blue light for complex 2, as shown in FIG.
3, with a t 112 of 53 seconds.A t 112 ofg.7 minutes was measured
for 1.
The presence of isosbestic points in the absorption spectra
indicated the direct conversion from starting material to a
single product. Samples of each complex after light activation
were subjected to analytical HPLC. The tris-polypyridyl
compounds are converted to bis-polypyridyl complexes with
the selective ejection of a biquinoline ligand in all cases, as
indicated by the peak with a retention time of32.1 minutes
(identified as the free biquinoline ligand). The phenanthroline
ligand was not observed in any of the chromatograms, and the
only free ligand that was detected in the mass spectra for all
samples was biquinoline. Without being bound by theory, the
selective labilization of the biquinoline indicates that the distortion due to the twisting of the ligand may drive the ejection
process, the breaking of the Ru-ligand bonds proceeds
through a step-wise mechanism, and fused ring systems such
as phenanthroline may re-coordinate the metal, preventing
ligand loss. The quinoline rings in the biquionline ligand can
rotate about the C 2 -C 2 • bond, inhibiting re-coordination.
The ability of the ruthenium complexes to damage DNA
upon light activation was determined by gel electrophoresis
with supercoiled pUC19 plasmid, as shown in FIG. 4. All
complexes induced a dose-dependent effect on the DNA
mobility, with increasing retention indicating photobinding
of the complex to the plasmid DNA. The decreased migration
on the gel with increasing concentration of complex is consistent with a DNA crosslinking effect. It should be noted that
intercalation also causes decreased migration in agarose gels,
but as the effect was not observed for 1 and 2 in the absence
of light, intercalation of the compounds is unlikely. Similar
results were obtained for Ru(phen)2 (H 2 0 ) 2 , which covalently
modifies DNA.
The compounds did not appear to photocleave DNA, as no
increase in the linear or relaxed circle forms of DNA
were observed. A significant loss of the ethidium bromide
(EtBr) signal was observed for the light activated 1, 2, and
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TABLE 1
Selected bond lengtbs (A). bond angles (c). and torsion angles (c) for compounds 1 and 2.
Compound 1
Ru-Nl-biq

Ru-N2-biq
Ru-N3-phen(l)
Ru-N4-phen(l)

Ru-N S-phen(2)
Ru-N6-phen(2)
N2-biq-Ru-N3-phen(l)
N4-phen(l)-Ru-NS-phen(2)

N 1-biq-Ru-N2-biq----C 10-biq
N 1-biq----C9-biq----C 10-biq-N2-biq

Compound 2
2.112(3)
2.095(3)
2.063(3)
2.056(3)
2.091(3)
2.091(3)
99.15(12)
82.75(12)
-20.72(4)
-5.62(5)

Ru-Nl-biq(l)
Ru-N2-biq(l)
Ru-N3-biq(2)
Ru-N4-biq(2)

Ru-NS-phen
Ru-N6-phen
N2-biq(l)-Ru-N3-biq(2)
N4-biq(2)-Ru-N5-phen

N l-biq(l)-Ru-N2-biq(l)----C 10-biq(l)
N l-biq(l)----C9-biq(l)----C lO-biq(l)-N2-biq(l)
N 4-biq(2)-Ru-N3-biq(2)----C27 -biq(2)
N 3-biq(2)----C27 -biq(2)----C28-biq(2)-N4-biq(2)

The complexes all underwent photo-substitution reactions
upon exposure to visible light. The kinetics of the ejection
process were followed by absorption spectroscopy, as shown
in FIG. 3. The number of sterically hindered ligands and the
corresponding distortion in the complex affected the rate of
the photosubstitution reaction, with an order of magnitude
variation in t 112 for the different structures. The wavelength
dependence of the photochemical process also correlated

60
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2.084(2)
2.079(2)
2.088(2)
2.093(2)
2.104(3)
2.098(2)
97.14(10)
80.14(9)
-20.41(19)
2.7(4)
-19.5(2)
12.1(4)

Ru(phen) 2 (H 2 0) 2 at concentrations above 15 f.LM. To determine if this signal loss was due to degradation of the DNA,
bands were excised, purified and quantified for DNA content.
Approximately go% of the plasmid was recovered from the
excised bands, despite a 9g% reduction of the EtBr signal.
Without being bound by theory, this suggests that the ruthenium interferes with the EtBr emission and/or the structure of
the ruthenium modified DNA prevents intercalation. The
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purified DNA exhibited the same decreased mobility pattern
when subjected to a second agarose gel, supporting a covalent, photo binding mechanism for I and 2. This may provide
an advantage over DNA photocleavage mediated by PDT
agents and other metal complexes that require oxygen and
generate single strand breaks, which may be readily repaired.
The photoreactivity of I and 2 was dependent on the wavelength of light used. Significant activity was retained upon
shifting to both red and near-IR light, as indicated by gel shift.
It should be noted, however, that the light intensity is significantly attenuated by the longer wavelength cut-off filters
(e.g., >600 nm). There is also diminished molar absorptivity
for the compounds in the red and near-IR region. Thus, more
intense red or near-IR light sources likely would increase the
apparent potency of the compounds. This is supported by the
fact that irradiation for longer times induced greater DNA
photobinding. Both complexes showed negligible reactivity
with the DNA in the dark.
Cytotoxicity studies were performed to determine if the
light-induced DNA damage translated to biological activity
in cancer cells. The complexes exhibited dose dependent
cytotoxicity in the HL-60 human leukemia cell line. The
activity of the compounds was also dependent on the light
dose, indicating that light-activation is correlated with cytotoxicity. The compounds were incubated with the cells for 12
hours prior to irradiation with blue (>400 nm), red (>600 nm),
and near-IR (>650 nm) light (Table 2). This potency is comparable to cisplatin, which was found to have an IC 50 value of
3.1 f.LM. Increasing the light dose increased the observed
potency. For example, compound 2 showed a 2-fold enhancement in potency upon increasing the irradiation time from 3 to
6 minutes with red light, recovering the activity measured
under irradiation with blue light. The superior activity of 2
compared to I with red and near-IR light irradiation is consistent with the presence of a longer wavelength absorption
feature extending past 700 nm. A phototoxicity index (PI)
value (the toxicity in the dark vs. the light) of 43 was found
with blue light for compound I. Compound 2 was more
potent than I with red- and near-IR light, exhibiting a PI of20
and 9.2, respectively.

flash chromatography, and converted to chloride salts for
testing.
Materials and General Methods
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All chemicals for this Example were obtained from commercial sources and were used without further purification.
Ru(bpy) 2 Cl 2 .2H 2 0 was purchased from Strem Chemicals
Inc. (Newburyport, Mass.) and 5-aminolevulinic acid hydrochloride (ALA) was purchased from Alfa Aesar (Ward Hill,
Mass.).
All 1 H NMR were obtained on a Varian Mercury spectrometer (400 MHz; Palo Alto, Calif.) and chemical shifts reported
relative to the residual solvent peak of acetonitrile at o 1.93.
The 13 C chemical shifts are reported relative to CD 3 CN at o
1.39. Electrospray ionization (ESI) mass spectra were
obtained on a Varian 1200L mass spectrometer. Absorption
spectra were obtained on an Agilent S453 Diode Array spectrophotometer (Santa Clara, Calif.). Photoexpulsion experiments were performed using a Dell200 Watt 141 OX projector
(for in vitro photoejection experiments) or 410 Watt 955
Model 900 AJH projector (for cell cytotoxicity studies) (Dell
Inc.; Round Rock, Tex.) fitted with an Edmund Optics filter
(NT43-935) (Barrington, N.J.). UV/Vis experiments were
performed in a 1-cm pathlength quartz cuvette located IS
inches from the projector. Kinetics were fit using the equation
for a single exponential with the Prism software package. Cell
survival was quantified using a Tecan Spectroflur Plus Microplate Reader (Tecan Systems, Inc.; San Jose, Calif.).
Furthermore, chloride salts of the ruthenium complexes
were injected on anAgilent II 00 Series HPLC equipped with
a model GI311A quaternary pump, GI315B UV diode array
detector and Chemstation software version B.01.03. Chromatographic conditions were optimized on a Colunm Technologies Inc. CIS, 120 A (250 mmx4.6 mm iuner diameter, 5
f.tm) (Downers Grove, Ill.) fitted with a Phenomenex CIS (4
mmx3 mm) (Torrance, Calif.) guard colunm. 15 f.LL injection
volumes of 30 f.LM solutions of the complex were used. The
detection wavelength was 2SO nm. Mobile phases used were
0.1% formic acid in dH 2 0 and 0.1% formic acid in HPLC

TABLE2
Photobiological activity in HL-60 cells.
Compound

2
Cisplatin

IC

A.ab/nm

Phototoxicity Index (PI)

(E/M- 1cm- 1 )

Dark

Blue (3 min)

Red (3 min)

Red (6min)

IR(25min)

Blue

IR

525 (8,300)
550 (4,950)

52.5
47.3
3.1

1.22
2.4
3.1

13.8
4.54
N.D.

7.63
2.29
N.D.

15.8
5.14
N.D.

43
19.7

3.32
9.2
N.D.

Example 2
In this Example three complexes with structural differences were explored to test the strain-mediated photoactivation approach (Table 3 ). The complexes were synthesized and
characterized as a racemic mixture of A and A enantiomers.
Ru(bpy )2 phen (3) was used as an unstrained control. In order
to distort the geometry about the octahedral metal center,
polypyridylligands with methyl substituents were incorporated into the Ru(II) complexes; these groups are directed
towards the other coordinating ligands, causing steric clashes.
The complexes were readily prepared under low light conditions by refluxing the precursor Ru(bpy )2 Cl 2 with the desired
ligand in ethylene glycol. They were purified by silica gel

grade acetonitrile (Fisher Brand; Pittsburgh, Pa.). The gradient is shown in the table below.
55

60

65

Time (minutes)

0.1% formic acid in dH 2 0

0.1% formic acid in MeCN

0
2

98
95
70
70
40

2

15
20
30
35
40

98
98

30
30
60
95
2
2
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All metal complexes were synthesized and handled in low
ambient light. The metal complexes were converted to the
chloride salts prior to biological testing to increase water
solubility. The ion exchange was accomplished by precipitation of the complex from dry acetone by the addition of
tetrabutylammonium chloride. The compounds were filtered
and stored in the dark. The synthesis of the 2,9-dimethyl dpq
ligand was performed according to known procedures.
Compound 4: Ru(bpy) 2 Cl 2 .2H 2 0 (200 mg, 0.384 mmol)
and 6,6'-dimethyl-2,2'-bipyridine (78 mg, 0.423 mmol) were
added to 8 mL of degassed ethylene glycol in a pressure tube.
The mixture was heated in the dark for 6 hours, allowed to
cool and poured into 50 mL of distilled water. Addition of a
saturated aq. KPF 6 solution produced a dark orange precipitate that was collected by vacuum filtration. The purification
of the solid was carried out by flash chromatography (silica
gel, 0.1% saturated KN0 3 , 2% H 2 0 in MeCN ramped to 9%
H 2 0) to give the pure complex. A saturated aq. solution of
KPF 6 was added, and the metal complex was extracted into
CH 2 Cl 2 . It was dried down to give a red solid. Yield: 297 mg
(87% ).
Compound 5: Ru(bpy) 2 Cl 2 .2H 2 0 (200 mg, 0.384 mmol)
and 2,9-dimethyldpq (150 mg, 0.577 mmol) were added to 8
mL of degassed ethylene glycol in a 15 mL pressure tube. The
mixture was heated with stirring in the dark for 6 hours. The
dark red solution was allowed to cool and poured into 50 mL
of distilled water. Addition of a saturated aq. KPF 6 solution
produced a dark orange precipitate that was collected by
vacuum filtration. The purification of the solid was carried out
by flash chromatography (silica gel, 0.1% saturated KN0 3 ,
2% H 2 0 in MeCN ramped to 9% H 2 0) to give the pure
complex.A saturatedaq. solutionofKPF 6 was added, and the
metal complex was extracted into CH 2 Cl 2 . It was dried down
to give a red solid. Yield: 284 mg (77%).
Compound 6: Ru(bpy) 2 phen.
Photoejection
It was observed that addition of the methyl groups to either
bpy (2,2'-bipyridyl) or the DNA intercalating ligand dpq
(dipyrido[3,2-f:2',3'-h]-quinoxaline) results in complexes
that undergo photochemical reactions upon exposure to light.
Irradiation of 4 and 5 in either acetonitrile or buffer with >450
nmlightusinga200Wprojectorandcut-offfiltersresultedin
substitution of solvent molecules for the polypyridylligand.
The photochemical reaction was conveniently followed by
UV/Vis absorption spectroscopy, as shown in FIG. 5.
The photo-ejection is both rapid and selective, with a t 112 of
2 minutes for 4 and clear isosbestic points at 351, 389, and
476 nm, highlighting the selectivity of the photo-labilization.
ESI-MS experiments identified the ejection of the 6,6'-dimethyl-2,2'-bpy ligand from compound 4, while compound 5
ejects the 2,9-dimethyl-dpq ligand. The reaction went to
completion for 4. The reaction kinetics are 30-fold faster for
4 than for 5, possibly due to the rigidity of the dpq ligand that
may enhance re-chelation, interfering with the stepwise dissociative bond breaking mechanism that releases the ligand.
Control compound 3 was photo-stable under the irradiation
conditions used. All complexes were stable the dark in aqueous solution at concentrations of 50 mM for months at room
temperature.
Biological Procedures
Plasmid-compound gel analysis: Plasmid pUC19 was
obtained from Bio-Rad (Hercules, Calif.), transformed into
DH5a cells and positive transformants were selected by
colony formation on Ampicillin LB-Agar plates. Colonies
were grown in LB and plasmid isolated using a Maxi-prep
plasmid isolation kit (Qiagen; Velno, Netherlands). Plasmid
amounts were quantified by UVNIS. For dosing studies, 40

f.tg/ml of plasmid was incubated with compound dosed from
0 to 500 f.LM in 96 well plates. They were incubated for 30 min
prior to light activation for 1 hour using a Dell 141 Ox 200 W
projector fitted with a >450 nm cut-off filter. Dark controls
were performed by keeping the DNA: compound mixtures in
the dark. The samples were incubated overnight after light
activation before gel analysis; the dark samples were also
incubated for the same time period. Linear plasmid and
relaxed circle plasmid were generated and run side-by-side
with compound treated samples. Linear plasmid was generated using the EcoRI restriction enzyme (New England
BioLabs; Ipswich, Mass.) following the manufacturers protocol. Single cut, relaxed circle, plasmid was generated using
the copper phenanthroline reaction. Reaction was carried out
in 10 mM phosphate buffer pH 7 .5, with 40 flg/ml plasmid, 1
mM DTT, 1 mM hydrogen peroxide, and 5 f.LM copper
phenanthroline for 30 min at 25° C. The addition of DTT
reduced the copper phenanthroline to the +1 charge state,
followed by reaction with peroxide created the damage to the
DNA. Samples were resolved on a 1% non-EB (ethidium
bromide) agarose gel followed by 40 minutes of staining with
0.5 flg/ml EB in Tris-Acetate buffer followed by 40 minutes
of destaining in Tris-Acetate before imaging.
Glutatione Assay:
The pUC19 plasmid was incubated at 25 f.tg/ml with 30
mM of either compound 4 or cisplatin nitrate in 10 mM
phosphate buffer pH 7 .5, with increasing amounts of gintathione (GSH) at 25° C. Cisplatin (30 f.LM) and compound 4
(30 f.LM) were co-dosed with increasing concentrations of
GSH. The concentrations of GSH were 0.01, 0.1, 1, 10, 40
mM, giving a molar ratio between the compounds and glutathione of a) 1:0.3, b) 1:3.3, c) 1:33, d) 1:333, e) 1:1333.
Compound 4 was activated with light for 1 hr as described
above followed by a 12 hr incubation in the dark, while
cisplatin nitrate was incubated with plasmid and GSH in the
dark for 12 hrs. Control reactions with pUC19 in the presence
and absence of GSH were carried out for 12 hrs in the dark
with 25 flg/ml plasmid and 40 mM GSH in 10 mM phosphate
buffer, pH 7 .5. The plasmid was resolved on a 1% agarose gel
as described above.
The results of the gel electrophoresis are shown in FIG. 6.
Cisplatin kinked DNA and caused unwinding, reducing its
mobility on agarose gels and impeding intercalation ofEtBr.
Cu(phen) 2 produced single strand breaks, generating relaxed
circular plasmid DNA. Exposure of ruthenium compounds
3-5 to visible light (200 W, 1 hour) in the presence of pUC19
plasmid produced both effects: DNA photocleavage (in the
case of compound 3), and DNA photo binding, which may be
crosslinking (in the case of 4). Compound 5 exhibited a combination of these two mechanisms. Light-induced DNA
single strand breaks produced by 3 are shown as the conversian of supercoiled DNA to relaxed circular form (FIG. 6A).
DNA photo binding for 4 and 5 is evidenced by the supercoiled DNA that migrated more slowly through the gel and
EtBr intercalation was diminished with increasing concentration of the Ru(II) complexes (FIGS. 6B and 6C). An additiona! form was observed with high concentrations of 5 that
migrated more quickly that the relaxed circular form (FIG. 6C
lanes 8-10). Without light no DNA damage or binding was
observed.
Unlike known agents, such as cisplatin, prodrug compounds 4 and 5 did not interact with GSH over a period of
days, as observed by UV/Vis spectroscopy. The photoactivated DNA crosslinking Ru(bpy) 2 species retained its ability
to damage DNA, even at higherGSH concentrations. FIG. 6D
shows the crosslinking of plasmid DNA by cisplatin and
light-activated compound 4 in the presence of increasing
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amounts of GSH. Cisplatin exhibited reduced crosslinking
efficacy with increasing levels of GSH, as indicated by
greater mobility of the DNA on the agarose gel. The active
form of 4 caused greater DNA binding than cisplatin. As
described below, cisplatin or compound 4 were co-dosed with
increasing concentrations ofGSH. GSH reduced cytotoxicity
for cisplatin, but not for compound 4.

irradiation. In contrast, photoreactive compounds 4 and 5
showed light-triggered toxicity. After irradiation, both compounds 4 and 5 produced single f.LM IC 50 values (Table 3 ). The
complexes were more potent than cisplatin when light activated and non-toxic in the dark, with dark IC 50 values over
100 f.LM for 5 and no dark toxicity observed up to a concentration of300 f.LM for 4.

TABLE3
Cytotoxicity IC 50 values in 2D and 3D cellular assays. The
phototoxicity index (PI) is the ratio of the dark and light IC 50 values. The
multicellular resistance (MCR) index is the ratio of the spheroid and monolayer
culture IC values.

Lig!!t IC 50 [uM]
Compound
Cisplatin
3
4
ALA

A549
HL60

A549

3.1(+0.2) 3.4(0.6)
81(+1.9) 40(+4)
1.6(+0.2) 1.1(+0.3)
2.6(+1.0) 1.2(+0.1)
16.2(+3.2) 21(+3.5)

Phototoxicity

Dark IC 50 [l!M]
A549

spheroid HL60
n.dd
>300
21.3(+2.3)
64.6(+4.7)
>300

A549

3.1(+0.1) 3.5(+0.6)
240(+9)
250(+5)
>300
150(+7)
108(+1.9) 250(+5)
>300
87.8(+5.5)

Index Pib

MCR

spheroid HL60 A549 Indexc
42(+3.6)
12.4
>300
6.3 >7.5
>300
>188 136
19.4
>300
216 208
54
>300
>18
4.2 >14

n.d. =not determined; see Dark IC 50 value.

Cell Survival Assay:
The HL60 promyelocytic leukemia cell line was obtained
fromATCC and cultured in IMDM media (Invitrogen; Carlsbad, Calif.) supplemented with 10% serum supreme (Lanza;
Basel, Switzerland) and penicillin/streptomycin at 37° C.
with 5% C0 2 . TheA549 cell line was donated and cultured in
DMEM supplemented with glutamax, 10% serum supreme,
and penicillin/streptomycin at 37° C. with 5% C0 2 . Cells
were plated in Optimem (Life Technologies; Carlsbad, Calif.)
supplemented with 1% serum supreme and penicillin/streptomycin at 30,000 cells per well in Costar 96 well flat bottom
clear tissue culture treated plates for HL60 and 1500 cells/
well for A549. The compounds were dosed from 0 to 300 f.LM,
incubated with the cells for 12 hours, and then activated for 3
minutes with light using a 410 W projector fitted with a >450
nm cut-off filter. The cells were then incubated for 72 hours
followed by the addition of Cell Titer Glo (Promega; Madison, Wis.) to determine viability. Dark controls were run in
parallel. The resulting luminescence was measured using the
SpectraFluor Plus Plate Reader (Tecan). Data were fit to an
equation for a sigmoidal dose response using the equation
below, where y, and yfare the initial and final signal intensities.

y;- YJ
Y = Yi + 1 + 1Q(logEc50 x)Hillslope

Cell cytotoxicity studies were performed in HL60 leukemia cells andA549lung cancer cells (see FIG. 7 and Table 3).
Cells were incubated with compounds for 12 hours in the dark
before irradiated with >450 nm light (410 W) for 3 minutes.
Dark controls were run in parallel. Cell survival was quantified 72 hours later through the use of anATP luciferase assay,
and confirmed by Trypan Blue staining and manual counting.
Cisplatin exhibited the same activity under light and dark
conditions. Control compound 1, which causes single strand
DNA breaks, exhibited only slightly enhanced activity upon
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The light activated Ru(II) complexes caused near or complete cell death, which can be a challenge with light activated
cytotoxic systems.
In Vivo Glutathione Assay:
A549 cells were plated in Optimem supplemented with 1%
serum supreme and penicillin/streptomycin in 96 well plates
as described above. The cells were allowed to adhere to the
plate for 12 hours and then were dosed with glutathione from
0 to 16 mM, followed immediately by either cisplatin at the
IC 100 or compound 4 at the IC 80 concentration. The IC 80 was
chosen for compound 4 since glutathione did not show a
cytoprotective effect in previous experiments with 4. Compound 4 was activated with 3 min a flight as described above,
and cytotoxicity measured 72 hours after compound activation and at the same time point for the dark samples. Cellular
viability was determined by measuring ATP concentration
with Cell Titer Glo (Promega). Data were fit to an equation for
sigmoidal dose response shown above using the Prism software package.
Tumor Spheroid Procedures:
A549 cells were seeded at 2,500 cells/well in 1.5% agarose
coated 96-well plates. After 7 days the spheroids were dosed
with compounds and incubated for 12 hrs. Following this,
they were activated by light for 3 minutes using a 410 W
projector fitted with a >450 nm cut-off filter, or kept in the
dark. Cellular viability was determined 72 hours after light
activation for the irradiated samples and at the same time
point for the dark samples by measuring ATP concentration
with Cell Titer Glo (Promega). Data were fit to an equation for
sigmoidal dose response shown above using the Prism software package.
3D tumor spheroids were used to test the compounds.
Spheroids provide a system that approximates the complexity
of in vivo tumors. These spheroids mimic the pathophysiology of tumors, including hypoxic/necrotic regions, changes
in cell shape, high proportions of quiescent cells, alterations
in gene expression profiles, and diminished permeability to
drugs. Spheroids exhibited the phenomena of multicellular
resistance (MCR), similar to the diminished efficacy of chemotherapeutics in vivo. To characterize the light-activated
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ruthenium compounds under more challenging and biologically relevant conditions, efficacy was assessed in a 3D tumor
model by forming tumor spheroids with A549 cells.
Spheroids of about 600 f.tm in diameter were dosed with
compounds and then either kept in the dark or irradiated with
>450 nm light for 3 minutes. Significant light-selective cytoxicity was observed for 4, with an IC 50 value of 21 f.LM, while
no cell death was observed up to 300 f.LM in the absence of
light. Under the same conditions, the IC 50 for cisplatin fell to
42 f.LM in the spheroid model, and the PDT drug ALA (aminolevulinic acid) had no effect. The activity of 5 was lower
than 4 in the spheroid, with a light-activated IC50 of 64 f.LM.
Thus, the compounds exhibited twice the potency of cisplatin in both monolayer and tumor spheroids. The MCR
index value is low for 4, similar to cisplatin (Table 3), which
has a MCR lower than that of many other chemotherapeutics.

(50 mL). Purification of the solid was carried out by flash
chromatography on Si0 2 . Elution with saturated aq. KN0 3 /
H 2 0/CH 3 CN (5/15/80) gave the pure complex. After column
purification the complex as the N0 3 - salt was dissolved in a
minimal volume of water, and a saturated aq. solution of
KPF 6 was added. The complex was extracted into CH 2 Cl 2 and
the solvent removed under reduced pressure to give a deep red
solid. Thus, the light-switch Ru(bpy) 2 dppz (7) was transformed into a complex 8 probe that combines DNA sensing
with ligand ejection photochemistry, as shown in FIG. 9, by
strain-inducing methyl groups incorporated at the 3 and 6
positions of the dppz ligand (3,6-dimethyl dipyridylphenazine, dmdppz).
Compounds 7 and 8 were converted to the cl- salt prior to
procedures. The PF 6 - salt of each complex was dissolved in a
minimal volume of acetone (1-2 mL), followed by the addition of a solution oft-butyl ammonium chloride (1 g dissolved
in 5 mL of acetone) producing a precipitate that was filtered
through glass wool, washed with acetone (50 mL) and eluted
with acetonitrile. The solvent was removed under reduced
pressure to give the pure complex.
To perform crystallography, all crystal manipulations
requiring exposure to light were conducted as rapidly as
possible. To this end, the crystal( s) were plunged directly into
liquid nitrogen and mounted using cryo-tongs. Single crystals
of compounds 7 and 8 were grown by slow evaporation of
methylene chloride in diethyl ether, mounted in inert oil and
transferred to the cold gas stream of the diffractometer. X -ray
diffraction data were collected at 90.0(2) K on a BrukerNonius X8 Proteum diffractometer with graded-multilayer
focused CuK(a) x-rays. Raw data were integrated, scaled,
merged and corrected for Lorentz-polarization effects using
theAPEX2 package. Corrections for absorption were applied
using SADABS and XABS2. The structure was solved by
direct methods (SHELXS-97) and difference Fourier
(SHELXL-97). Refinement was carried out against F2 by
weighted full-matrix least-squares (SHELXL-97), and
assessed with the aid of an R-tensor. Hydrogen atoms were
found in difference maps but subsequently placed at calculated positions and refined using a riding model. Non-hydrogen atoms were refined with anisotropic displacement parameters. Atomic scattering factors were taken from the
International Tables for Crystallography.
The crystal structures of racemic Ru(bpy) 2 dppz (7) and
Ru(bpy) 2 dmdppz (8) confirmed that addition of the methyl
groups induced distortion about the metal center (FIG. 10).
The Ru-N bonds were lengthened in the strained ligand,
with an average of 2.10 A for the Ru-N bonds in dmdppz, in
contrast to 2.07 A for dppz. The main distortion in compound
8 is a 15° bending of the dmdppz ligand from the normal plane
of the octahedral complex, due to the clash of the methyl
group with the auxiliary ligands. The bpy ligands in either
compound did not experience significant distortions.
Complex 8 was rather unreactive in water, exhibiting slow
photodecomposition when exposed to visible light (A.>400
nm; t 112>8 hours), suggesting a more discerning switch that
could exploit triggers with light. The photoreactivity was
increased by more than an order of magnitude in the presence
of duplex DNA oligonucleotides and calf thymus (CT) DNA,
with t 112 values of31-41 minutes, as shown in Table 4. The
photoejection process was characterized by both a red shift in
the absorption spectra and decreased extinction coefficient.
Ligand ejection was selective, as indicated by the presence of
isosbestic points in the UVNis spectra taken as a function of
irradiation time (FIG. 9B). It appeared that only the dmdppz
ligand was ejected, and the photoreaction led to covalent
metalation of the DNA.
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Example 3
This Example describes a novel ruthenium complex containing a dppz derivative that undergoes photochemical
ligand substitution reactions in the presence of DNA. The
compound exhibited selective photochemistry to generate a
ligand-deficient and reactive metal center, along with a free
coordinating ligand, in the presence of nucleic acids and
organic solvents. The compound was sensitive to the DNA
tertiary structure, displaying different reactivities in duplex
and G-quadruplex DNA, providing a mechanism for the
development of DNA structure-selective probes and effectors.
Chemicals used for synthesis were purchased from suppliers and used without further purification. Calf thymus (CT)
DNA was purchased from Sigma-Aldrich, re-suspended in
buffer (50 mM NaCl, 5 mM Tris buffer, pH 7 .0) and sonicated
(bath sonicator for 40 min followed by 10-15 1 sec pulses
with a Branson Sonifier 250 (duty cycle=90% and output
control=2; Danbury, Conn.) to provide shorter strands. The
15-mer oligonucleotide A was purchased from Integrated
DNA Technologies (Coralville, Iowa) and the G-quadruplex
sequence was purchased from Eurofins Scientific (Luxembourg), re-suspended, and annealed prior to use. The forward
sequence for the 15-mer oligonucleotide A is 5'-CCT-CTCTGG-TTC-TTC-3' and the reverse sequence is 5'-GAAGAA-CCA-GAG-AGG-3'. The 15-mer oligonucleotide was
re-suspended in dH 2 0 and annealed by heating at 90° C. for
5 min then cooling slowly to ambient temperature and stored
at -20° C. The G-quadruplex sequence is 5'-[AGGG
(TTAGGG) 3 ]-3'. The G-quadruplex was re-suspended in
buffer (10 mM potassium phosphate, 100 mM KCl, pH 7.0)
and annealed by heating at 90° C. for 5 min then cooling
slowly to ambient temperature, followed by incubation at 4°
C. overnight, as previously reported. 1
Briefly, dipyrido[3.2-a:2',3'-c]phenazine (dppz) and
Ru(bpy )2 dppz (7) were prepared by known methods. To prepare 3,6-Dimethyl-dipyrido[3,2-a:2',3'-c]phenazine (dmdppz), dimethyl-dipyrido[3,2-a:2',3'-c ]phenazine was first
prepared by known methods modified to start with 2,9-dimethylphendione. Next, to prepare Ru(bpy) 2 dmdppz (8),
Ru(bpy) 2 Cl 2 .2H 2 0 (501 mg, 0.963 mmol) and 3,6-dimethyldipyrido[3,2-a:2',3'-c]phenazine (328 mg, 1.057 mmol) were
added to 16 mL of degassed ethylene glycol in a 38 mL
pressure tube. The mixture was heated at 150° C. with stirring
and protected from light. After 16 hours the red solution was
cooled to room temperature and poured into 50 mL of distilled water. Addition of a saturated aqueous KPF 6 solution
produced a deep red precipitate that was collected by vacuum
filtration and washed with dH 2 0 (50 mL) and diethyl ether
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TABLE4

beneficial to induce photoejection, but environmental factors
may also affect other nonradiative decay processes.

Photophysical and photochemical properties for 7 and 8 for various
reaction conditions.
Experimental
Conditions[a]
H20
D20
CH2Cl2
DMF
CTDNA
15 mer oligonucleotide
A
G-Quadrup lex
BSA

Am=(nm) (7)
605 (weak)
596
638
619
615
613

Example 4

Half-life
(minutes) (8)
>480
140 ± 10
0.5 ± 0.05
25 ± 2
41 ± 2
31 ± 0.5

10

13.5 ± 1
146 ± 8
15

The distortion of compound 8 did not appear to significantly affect the DNA binding affinity, as similar K 6 values of
1x107 and3x10 7 M- 1 were determined for racemic mixtures
of7 and 8 with CT DNA. Intercalation ofboth complexes was
consistent with the reduced mobility of supercoiled plasmid
DNA in agarose gels, and the modulation of the absorption
spectra in the presence of DNA, characterized by hypochromism of both the Jt-Jt* of the dppz ligand and the MLCT
transitions, with maximal effect at a ratio of 2: 1 DNA base
pairs to metal center. Thus, the strained complex retained
DNA-sensing capabilities of other Ruii "light-switch" molecules and photochemical reactivity.
Alternative tertiary structures of DNA provide potential for
greater selectivity in gene and cellular regulation than double
stranded motifs, and G-quadruplex structures are medically
relevant targets for cancer research and therapies. Complex 8
was tested as a photochemical probe for the telomeric G-quadruplex structure using the sequence [AGGG(TTAGGG) 3 ].
Upon binding the quadruplex, the photoejection rate for 8
increased 3-fold compared to standard double helix CT DNA,
giving a t 112 of 13.5 minutes.
The selectivity of the probe for DNA was compared to
protein by testing the ejection with bovine serum albumin
(BSA). There was no observable emission for 7 in the presence of BSA, and 8 appeared to photodecompose, with no
isobestic points in the absorption spectra and a t 112 of 146
minutes. The reactivity with a hydrophobic protein is similar
to the behavior in water.
The photochemical behaviour of 8 paralleled the photophysical characteristics of unstrained Ruii complexes containing the dppz ligand. For example, the emission intensity
of 7 and other dppz complexes as well as of 8 increased in
nonpolar, aprotic solvents (t 112>8 hrs in water, t 112=0.5 min in
CH 2 Cl 2 ). The luminescence of Ruii dppz complexes was
greater in D 2 0 than H 2 0; and the ejection of 8 showed a
similar isotope effect of >3.4.
A proposed Jablonski diagram in FIG. 11 illustrates the
interplay between different states. The "bright" and "dark"
states are in thermal equilibrium as a function of the environment, and the dissociative 3 MC state can be accessed only
from the "bright" state. Population of the "dark" state is
enhanced in solvents such as water, and results in alternative
non-radiative decay pathways that reduce the yield of photoejection. Without being bound by theory, the data suggests
that the complex 8 undergoes ligand ejection photochemistry
efficiently under conditions that destabilize polar charge
transfer states and reduce population of the "dark" state
MLCT and it associated non-radiative decay pathways.
The present ruthenium complex therefore act as a dual
photochemical DNA sensor and metalating agent. Strain is
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This Example compares the synthesis and characterization
of exemplary Ru(II) complexes having positive and negative
overall charges. The compounds include Ru(bathophenanthroline) 3 (9), which is hydrophobic with a high DNA binding
affinity, and Ru(bathophenanthorlinedisulfonate )3 (1 0),
which is hydrophilic with a high affinity for proteins. Both
complexes are efficient singlet oxygen C0 2 ) generators with
the same quantum yields for 1 0 2 production (<I> ,j.) and similar
molar extinction coefficients (E). Compound 9 carries a +2
overall charge while 10 has a -4 overall charge.
Table 5 provides a summary of physical and photophysical
characteristics of the two complexes. This Example shows
that the compounds have differences in potency, cellular
uptake, localization, and mechanism of cytotoxicity. This
Example also shows that negatively and positively charged
Ru(III) complexes can be compatible as PDT agents.
TABLES
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Physical and Photophysical Properties of9 and 10
Property

Compound 9

Compound 10

Charge
Log P
Am=(nm)
1
1
E (M- cm- )
Aem(nm)

+2
1.8 ± 0.02
460
29,500
632
0.101
0.42

-4
-2.2 ± 0.12
462
29,300
632
0.176
0.43

<l>PL
<I>,.,
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DNA Damage and Cytotoxicity
As both 9 and 10 are efficient catalysts for the light-activated generation of 1 0 2 (<I> ,j.=0.42, 0.42). Their DNA damaging properties were assessed with p UC19 plasmid DNA using
gel electrophoresis. Serial dilutions of the compounds (0-500
f.LM) were mixed with 40 flg/mL pUC19 plasmid DNA in 10
mM potassium phosphate buffer (pH 7.4) protected from
light or irradiated with a 200 W light source for total light
doses of 40 J/cm2 blue filtered light (>400 nm). Samples were
then incubated for 24 hours at room temperature protected
from light. Controls were prepared to simulate single and
double strand DNA breaks, and the DNA samples resolved on
agarose gels.
Samples were resolved using 1% agarose gels prepared in
tris-acetate (TA) buffer. Each lane was loaded with 0.3 flg of
pUC19 and the samples run for 90 minutes at 100 mV. The
gels were stained with 500 ng/mL ethidium bromide in TA
buffer at room temperature for 40 minutes. The gels were
subsequently washed with fresh TA buffer at room temperature for 40 min then imaged using a ChemiDoc™ MP System
from Bio-Rad.
Compound 9 binds strongly with DNA, and precipitation
of the complex with the DNA was observed at concentrations
above 31.3 f.LM both in the light and in the dark (FIG. 12A). In
contrast, 10 is a more hydrophilic molecule, and the negatively charged sulfonate functional groups were anticipated to
cause electrostatic repulsions between the complex and the
negatively charged backbone of the DNA. DNA precipitation
or smearing was not observed with up to 500 f.LM of 2 (FIG.
12B). However, when exposed to light both 9 and 10 induced
single strand DNA breaks, creating relaxed circular plasmid.
However, for 10, the amount of relaxed plasmid did not
exhibit any concentration dependence above 125 f.LM, sug-
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The emission of9 and 10 was measured inA549 cells using
gesting either a reduction in <I> ,j. as the concentration of the
complex is increased, or alternative quenching mechanisms
anApoptome microscope. The relative rates of uptake of each
that impede DNA damage.
of the complexes were analyzed as a function of time, and
As both compounds are capable of light-induced DNA
both 9 and 10 were visible inside cells as early as 2 hours after
damage, the cytotoxicity of 1 and 2 were evaluated in the 5 compound addition, consistent with the flow data and the
A549 human non-small cell lung cancer, the HL60 human
ICP-OES results. Images were taken at 2, 8, 18 and 24 hours,
promyelocytic leukemia, and the Jurkat human T lymphoand
intracellular levels ofboth complexes appeared to plateau
blastoid cell lines in presence and absence of3 J/cm2 of>400
around 8 hours. The uptake data showed good agreement
2
nm light. A549 cells were grown in 75 cm culture flasks in
between the three techniques and two cell lines, suggesting
DMEM supplemented with 10% FBS and 1% pen-strep 10
similar behavior in adherent and suspension cell lines.
(DMEM) at 37° C., 5% C0 2 . Cell media was replaced twice
Differences in the intracellular localization of 9 and 10
a week and cells were maintained below 70% confluence.
were evaluated by determining colocalization of lumines2
HL60 cells were grown in 75 cm culture flasks in IMDM
cence of the compound and fluorescent markers of organelles
supplemented with 10% FBS and 1% pen-strep (IMDM) at
37° C., 5% C0 2 . HL60 cells were diluted 1:5 once a week 15 in A549 cells. Overlap in signals between the compounds,
cellular nucleus, mitochondria and lysosome was measured
with IMDM to maintain a cell concentration below 2x10 6
over a 24 hour period. FIG. 13 shows the 8 hour time point,
cells/mL.
which
demonstrates that 9 and 10 have different localization
The IC 50 values across the cell lines for 1 ranged from 0.62
profiles. Compound 9 substantially localized to lysosomes
to 3.75 f.LM in the dark. In the presence oflight, potency was
increased to a range of 0.075 to 0.35 f.LM, resulting in an 20 and the mitochondria in the absence of light, while 10
remained primarily in the cytosol. Exposure to light did have
averagephototoxicity index (PI=IC50 ( dark)/IC 50 light) of! 0some impact on compound localization, where 9 induced
to 20-fold (FIG. 12, Table 5).
The high toxicity of 9 in the absence of light is in marked
nuclear localization of the mitochondrial and lysosome markcontrast to the behavior of 2, where no toxicity was observed
ers (FIGS. 13A and 13B), suggesting that photo-induced
in the dark at concentrations up to 300 f.LM across all cell lines. 25 damage mediated by 9 reduced the integrity of the nuclear
Compound 10 was effective in killing cells only when irradimembrane. 10 was primarily observed in lysosomes after
ated, with IC 50 values ranging from 3.3 to 17.25 f.LM, consisirradiation, and did not co-localize with mitochondria (FIGS.
tent with the concentrations required for in vitro DNA dam13A and 13B). In addition, irradiation in the presence of 10
age. This provides for a large therapeutic window, as cell
did not result in the appearance of organelle markers in the
death was not observed for samples in the absence of irradia- 30 nucleus, suggesting the nuclear membrane remained intact.
tion.
Neither 9 nor 10 was found to associate with the cell memCompound 9 was toxic to cells upon irradiation and
brane or membranes of organelles.
induced cell death more rapidly than traditional DNA damMitochondrial Function and Time Dependence for Cell
aging agents such as cisplatin. Upon treatment with 9 and
Death
irradiation, cell death was observed within 2 hours. Cell death 35
Without being bound by theory, compound 9 localized
was slower for the samples kept in the dark, with approxiwithin mitochondria, which may account for its toxicity in the
mately 30% viable cells remaining at 24 hours. For comabsence of irradiation. To determine if the interactions of
pound 10 70% of viable cells remained at 24 hours and 55%
either 9 or 10 with the mitochondria resulted in reduced
remained at 48 hours after irradiation. The disparity in the
potencies, therapeutic windows, and rates of cell killing for 40 mitochondrial function, mitochondrial membrane potential
was measured using tetramethylrhodamine ethyl ester
the two compounds and similar ability to sensitize 1 0 2 sug(TMRE). TMRE is a cationic dye that accumulates in active
gested that they were acting through different cellular mechamotochondria as a result of the negative membrane potential
msms.
Cellular Uptake and Subcellular Localization
(lnjJm). Inactive or depolarized mitochondria exhibit a
Both 9 and 10 were emissive, allowing for direct visual- 45 decreased membrane potential and TMRE does not localize
in these organelles. Compound 9 induced rapid and complete
ization of their cellular uptake and localization. Flow cytometry and fluorescence microscopy were used to provide reladepolarization of mitochondria both in the dark and upon
tive uptake values, the time dependence of compound uptake,
irradiation (FIGS. 14A and 14B).
and information on the subcellular localization of the comCell viability did not parallel mitochondrial potential.
pounds. 9 was assayed at 5 f.LM while 20 f.LM of 10 was so Mitochondrial function was completely impaired at 2 hours
assayed. Flow cytometry with HL60 cells revealed greater
post treatment with 9 in the dark, viability decreased slowly,
uptake of9 compared with 10 at time points of2 and 24 hours,
with 44±6% viable cells remaining after 24 hours. In contrast,
with an 11.6-fold increase and 8.2-fold increase in signal
both mitochondrial function and cell viability fell to about 0%
respectively. Between the time points of 2 and 24 hours, the
within 2 hours of irradiation. Thus, while 9 impedes mitoaverage emission of cells incubated with 9 increased by 2.8- 55 chondrial function within 2 hours even in the absence oflight,
fold while the amount of 10 increased by 4-fold. This data was
irradiation induced additional damage that resulted in cell
supported by direct quantification of the number of ruthenium
death along with the loss of mitochondrial function.
atoms per cell using Inductively Coupled Plasma Optical
Compound 10 did not significantly reduce the mitochonEmission Spectroscopy (ICP-OES). The relative amount of
drial potential either when irradiated or in the dark over a 24
compound 9 in cells versus the cell media increased appro xi- 60 hour period. Irradiation did reduce cell viability to 70±12% at
mately 4-fold from 2 to 24 hours, from 5.6% to 22%. Less of
2 hours and 59±4% after 24 hours, but this occurred without
a significant decrease in the relative mitochondrial potential
compound 10 entered the cells, with a maximal percentage
uptake of0.7% at 24 hours. This degree of uptake is compa(FIG. 14D), indicating 10 did not act through inhibition of
mitochondrial function. This suggests that rapid mitochonrable to cisplatin dosed at the same concentration (20 f.LM,
0.8% at 24 hours). Irradiation increased the amount of 10 65 dria failure may be connected to the dark toxicity of9, and the
lack of mitochondrial localization and inhibition be conwithin the cells to 1.6%. Complete cell death was observed
nected to the limited dark toxicity of 10.
with 9 within 2 hours of light exposure.
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The disconnect between the mitochondrial potential and
cell viability for componnd 9 in the dark may also indicate
that disruption of mitochondrial activity does not lead to
immediate cell death.
Mechanism of Cell Death
Given the different cellular localization properties and time
profiles for cell death induced by 9 and 10, the mechanism of
cell death was investigated. Indicators of apoptotic cell death
(activation of PARP and caspase 3 through proteolysis) were
determined in HL60 cells treated with either 9 or 10 (FIGS.
15A and 15B). The known apoptotic inducing compounds,
cisplatin and doxorubicin, were rnn in parallel. Compound 9
induced the proteolytic activation of both PARP and caspase
3 within 2 hours of irradiation and was maximal after 8 hours
(FIG. 15). In the absence oflight, PARP and caspase 3 were
observed with 9, but after 18 and 24 hours and to a lesser
degree. In the absence of irradiation the amount of inactive
procaspase 3 did not change.
Exposure of 10 to light induced PARP as early as 2 hours,
and increasing amounts of PARP were observed over the
course of 24 hours (FIG. 15). The increase in the level of
activated caspase 3 occurred on a slower time scale than
PARP cleavage, with the protein observed at 18 and 24 hrs.
Thus, the irradiated samples may possibly nndergo apoptosis
that is not primarily signaled through caspase 3. Cells treated
with 10 and protected from light did not display PARP or
caspase 3 cleavage, indicating limited cytotoxicity in the
absence of light. The level of procaspase 3 did not change
over 24 hours.
Since 10 showed PARP induction without significant
caspase 3 activation, as compared to 9 and cisplatin or doxorubicin, a mechanism of cell death through necrosis was
explored. The generation of an alternate 55 kDa PARP fragment was determined by immnnoblot as a marker for necrosis
with 10% (v/v) ethanol used as a control that induces necrosis. Exposure of HL60 cells to 9 produced this fragment at
significant levels both when protected from light and when
irradiated, consistent with necrosis. Cisplatin and doxorubicin also produced this cleavage product, indicating that some
cells had progressed into necrosis. In contrast, cells exposed
to 10 both in the presence and absence of irradiation produced
a lower level of the 55 kDa PARP fragment, similar to the
untreated cells, suggesting necrosis was not a significant cell
death pathway for this componnd.
To further analyze the mechanisms of cell death induced by
9 and 10, the degradation pattern of genomic DNA was investigated. DNA laddering was observed as a result of DNA
fragmentation stemming from the execution phase of apoptosis. In contrast, necrotic cell death lacked this characteristic
laddering effect, allowing differentiation between these two
mechanisms. H L60 cells were exposed to the Ru(II) complexes, cisplatin, and 10% ethanol, followed by genomic
DNA isolation and resolution by gel electrophoresis. The
apoptosis inducer, cisplatin, initiated DNA fragmentation
resulting in a laddering pattern on the gel (FIG. 15B). This
laddering was absent in the cells treated with ethanol and
compounds 9 and 10 in the dark. However, both componnds
9 and 10 displayed similar laddering patterns as cisplatin
when irradiated, suggesting apoptosis is a major cell-death
pathway for both componnds when irradiated. In contrast,
given the cytotoxicity of 9 in the dark and the presence of the
55 kDa PARP fragment, it appears that necrotic cell death is
one pathway for 1. For componnd 10 the absence of DNA
laddering may be a result of the lack of cytotoxicity of the
negatively charged compound.
Thus, ligand modifications of the present complexes can
provide componnds with divergent physical properties and

biological activities. Compound 9, having high DNA affinity,
localized to the mitochondria and induced rapid membrane
depolarization and necrotic cell death. Componnd 10, with an
overall -4 charge, was taken up into cancer cells to a sufficient
degree to mediate light-induced cell death through an apoptotic pathway.
Example 5
10

15

This Example describes additional specific embodiments
the presently-disclosed subject matter. The structure, light
IC 50 , dark IC 50 , and phototoxicity index (i.e., dark IC 50/light
IC 50 ) for each compound is given below. The methods for
making and characterizing the componnds are based on the
methodologies described in the previous examples.
TABLE6
Physical and Photophysical Properties Exemplary Compounds

20
Structure
Cisplatin
Ru(bpy)o-6,6'dmbpy
25 Ru(bpy)odmdpq
Ru(bpy )odmphen
Ru(bpy )odmdppz
Ru(bpy)obathocuprione
Ru(dmphen)obpy
Ru(dmphen)obathophen
Ru(dmphen)odpq
30
Ru(dmphen)odppz
Ru(dmphen)ophen

35

Light IC 50
(fJM)

Dark!C 50
(f!M)

3.1
1.5
0.6
0.4
14
3.3
1.2
1.7
0.22
0.5
0.14

3.1
300
250
65
27
150
4.5
250
150
35

Phototoxicity
Index

200
400
20
4.6
8.18
125
2.5
1,130
300
250

Bpy = 2,2'-bipyridine
Phen = 1,10-phenanthroline
Dmphen = 2,9-Dimethyl-1, 10-phenanthroline
6,6'-dmbpy = 6,6'-dimethyl, 2,2'-bipyridine
dpq = dipyrido[3,2-f:2',3'-h]-quinoxaline
dppz = dipyrido[3,2-a:2',3'-c]phenazine
dmdpq = 2,9-dimethyl dpq
dmdppz = 2,9-dimethyl dppz
bathophen = bathophenanthroline

40

45

50

55

60

65

While the following terms used herein are believed to be
well nnderstood by one of ordinary skill in the art, definitions
are set forth to facilitate explanation of the presently-disclosed subject matter.
Unless defined otherwise, all technical and scientific terms
used herein have the same meaning as commonly understood
by one of ordinary skill in the art to which the presentlydisclosed subject matter belongs. Although any methods,
devices, and materials similar or equivalent to those described
herein can be used in the practice or testing of the presentlydisclosed subject matter, representative methods, devices,
and materials are now described.
Following long-standing patent law convention, the terms
"a", "an", and "the" refer to "one or more" when used in this
application, including the claims. Thus, for example, reference to "a compound" includes a plurality of such compounds, and so forth.
Unless otherwise indicated, all numbers expressing quantities, properties, and so forth used in the specification and
claims are to be understood as being modified in all instances
by the term "about". Accordingly, unless indicated to the
contrary, the numerical parameters set forth in this specification and claims are approximations that can vary depending
upon the desired properties sought to be obtained by the
presently-disclosed subject matter.
As used herein, the term "about," when referring to a value
or to an amount of mass, weight, time, volume, concentration
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or percentage is meant to encompass variations of in some
embodiments ±20%, in some embodiments ±10%, in some
embodiments ±5%, in some embodiments ±1 %, in some
embodiments ±0.5%, and in some embodiments ±0.1% from
the specified amount, as such variations are appropriate to
perform the disclosed method.
As used herein, ranges can be expressed as from "about"
one particular value, and/or to "about" another particular
value. It is also understood that there are a number of values
disclosed herein, and that each value is also herein disclosed
as "about" that particular value in addition to the value itself.
For example, if the value "10" is disclosed, then "about 10" is
also disclosed. It is also understood that each unit between
two particular units are also disclosed. For example, ifl 0 and
15 are disclosed, then 11, 12, 13, and 14 are also disclosed.
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What is claimed is:
1. A compound of the following formula:

each R4 is H, amine, amide, alkyl, aryl, SR4 , PR4 , 0,
OR4 , halogen, or S03 H.
5. The compound of claim 1, wherein at least one ofX 1 , X 2 ,
and X 3 are selected from:

+1-m

10

wherein:
ligands X 1 , X 2 , and X 3 , the same or different from one
another, are selected from bidentate nitrogen heterocycles, optionally substituted with one or more of alkyl,
aryl, amine, C(O), C(O)R, S, S(R), 0, O(R), amide, SR4 ,
PR4 , OR4 , halogen, S03 H, alkylamino and P, wherein R
is selected from H, OH, alkyl, and aryl;
m is -6 to +6; and
at least one of the ligands Xu X 2 , and X 3 is a straininducing ligand and are released when the compound is
exposed to light, wherein the ligands XI, X2, and X3 are
selected from pyridyls, phenanthrolines, quinolines, 6
membered heteroaryl rings containing one nitrogen
atom, or a combination thereof, and are optionally fused
to a 6-membered carbocyclic ring or 6 membered heteroaryl ring containing 1 or 2 nitrogen atoms, and are
optionally substituted with one or more of alkyl, aryl,
amine, C(O), C(O)R, S, S(R), 0, O(R), amide, SR4 , PR4 ,
OR4 , halogen, S03 H, alkylamino and P, wherein R is
selected from H, OH, alkyl, and aryl; or
a pharmaceutically acceptable derivative thereof.
2. The compound of claim 1, wherein at least one ofX 1 , X 2 ,
and x3 is a strain-inducing ligand having bond lengths and/or
bond angles that deviate by 5% or more relative to the ideal
bond lengths and/or bond angles determined by VSEPR.
3. Thecompoundofclaim1, whereinatleastoneofX 1 ,X 2 ,
and X 3 are selected from polypyridyl.
4. The compound of claim 1, wherein at least one ofX 1 , X 2 ,
and X 3 are selected from:

15
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25

wherein
each R 1 is independently selected from H, amine, amide,
alkyl, aryl, SR4 , PR4 , 0, OR4 , halogen, or S03 H, R4
being H, alkyl, or aryl, or wherein R 1 and R3 taken
together with the carbon atoms to which they are
bonded, form a substituted or unsubstituted ring containing about 4-6 ring carbon atoms that optionally
include one or more N; and
each R 2 is H, amine, amide, alkyl, aryl, SR4 , PR4 , 0,
OR4 , halogen, or S03 H.
6. The compound of claim 1, wherein at least one ofX 1 , X 2 ,
and X 3 are selected from:
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wherein
eachR 1 is independently selectedfromH, amine, amide,
alkyl, aryl, SR4 , PR4 , 0, OR4 , halogen, or S03 H, R4
being H, alkyl, or aryl, or wherein R 1 and R3 taken
together with the carbon atoms to which they are
bonded, form a substituted or unsubstituted ring containing about 4-6 ring carbon atoms that optionally
include one or more N;
each R 2 is H, amine, amide, alkyl, aryl, SR4 , PR4 , 0,
OR4 , halogen, or S03 H;
each R3 is independently selected from H, amine, amide,
alkyl, aryl, SR4 , PR4 , 0, OR4 , halogen, or S03 H, or
wherein R3 and R4 taken together with the carbon
atoms to which they are bonded, form a substituted or
unsubstituted ring containing about 4-6 ring carbon
atoms that optionally include one or more N; and
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when the at least one of Xu X 2 , and X 3 is

-continued
0

and

10

wherein when the at least one of Xu X 2 , and X 3 is

n is 2 or 4.
7. The compound of claim 1, wherein at least one ofX 1 , X 2 ,
and X 3 are a methylated bidentate nitrogen heterocycle.
8. The compound of claim 1, according to the formula:

15

20

n is from 1 to 16,
when the at least one of Xu X 2 , and X 3 is
25

30

9. The compound of claim 1, according to the formula:

n is 5, 7, or 9;

when the at least one of Xu X 2 , and X 3 is
35

40

n is 2 or 4;

when the at least one of Xu X 2 , and X 3 is

45
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n is 4 or 8;

when the at least one of Xu X 2 , and X 3 is
0

0
60
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n is 4 or 8; and

10. The compound of claim 1, according to the formula:
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11. The compound of claim 1, according to the formula:

17. The compound of claim 16, wherein the therapeutic
agent is hydroxyquinoline.
18. The compound of claim 1, wherein the light includes a
wavelength of about 500 nm to about 1000 nm.
19. The compound of claim 1, wherein m is less than zero.
20. A pharmaceutical composition, comprising a compound of the following formula:
10

+1-m

15

wherein:
ligands X 1 , X 2 , and X 3 , the same or different from one
another, are selected from bidentate nitrogen heterocycles, or a combination thereof and are optionally substituted with one or more of alkyl, aryl, amine, C(O),
C(O)R, S, S(R), 0, O(R), amide, SR4 , PR4 , OR4 , halo25
gen, S03 H, alkylamino and P, wherein R is selected
from H, OH, alkyl, and aryl; and
m is -6 to +6; and
at least one of the ligands Xv X 2 , and X 3 is a straininducing ligand and are released when the compound is
30
exposed to light, wherein the ligands X1, X2, andX3 are
selected from pyridyls, phenanthrolines, quinolines, 6
membered heteroaryl rings containing one nitrogen
atom, or a combination thereof, and are optionally fused
to a 6-membered carbocyclic ring or 6 membered het35
eroaryl ring containing 1 or 2 nitrogen atoms, and are
optionally substituted with one or more of alkyl, aryl,
amine, C(O), C(O)R, S, S(R), 0, O(R), amide, SR4 , PR4 ,
OR4 , halogen, S03 H, alkylamino and R, wherein R is
selected from H, OH, alkyl, and aryl; or
40
a pharmaceutically acceptable derivative thereof; and
a pharmaceutically-acceptable carrier.
21. A method of treating lung cancer or leukemia in a
subject, comprising:
administering an effective amount of the compound to the
45
subject, the compound including the following formula:
20

12. The compound of claim 1, according to the formula:

~

~

N

N~

u

13. The compound of claim 1, according to the formula:

+1-m

50
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14. The compound of claim 1, further comprising a targeting agent.
15. The compound of claim 14, wherein the targeting agent
selected from folate, estrogen, and erlotinib.
16. The compound of claim 1, wherein at least one of the
ligands is a therapeutic agent.

65

wherein:
X 1 , X 2 , andX 3 , the same or different from one another, are
selected from bidentate nitrogen heterocycles, and
m is -6 to +6; and
at least one of the ligands Xv X 2 , and X 3 is a straininducing ligand and are released when the compound is
exposed to light, wherein the ligands X1, X2, andX3 are
selected from pyridyls, phenanthrolines, quinolines, 6
membered heteroaryl rings containing one nitrogen
atom, or a combination thereof, and are optionally fused

US 9,290,528 Bl
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to a 6-membered carbocyclic ring or 6 membered heteroaryl ring containing 1 or 2 nitrogen atoms, and are
optionally substituted with one or more of alkyl, aryl,
amine, C(O), C(O)R, S, S(R), 0, O(R), amide, SR4 , PR4 ,
OR4 , halogen, S03 H, alkylamino and P, wherein R is
selected from H, OH, alkyl, and aryl; or

48
-continued

5

a pharmaceutically acceptable derivative thereof; and
exposing a site of the subject to light after the step of
administering the compound.

10

22. The method of claim 21, wherein, in the exposing step,
the compound releases one or more ofX 1 , X 2 , and X 3 .
23. The method of claim 21, wherein at least one ofXu X 2 ,
and X 3 are polypyridyl.

15

24. The method of claim 21, wherein at least one ofXu X 2 ,
and X 3 are selected from:

HOOC

COOH
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0

wherein when the at least one of Xu X 2 , and X 3 is
0

~N

~N

N

10

N

n is from 1 to 16,
when the at least one of Xu X 2 , and X 3 is

15

20 n

is 5, 7, or 9;
when the at least one of Xu X 2 , and X 3 is
0

25

30

n is 2 or 4;

when the at least one of Xu X 2 , and X 3 is
35

n

40

He__/\

n is 4 or 8;
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when the at least one of Xu X 2 , and X 3 is
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n is 4 or 8; and
when the at least one of Xu X 2 , and X 3 is
0

and

n is 2 or 4,

0
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25. The method of claim 21, wherein at least one ofXu X 2 ,
and X 3 are a methylated bidentate nitrogen heterocycle.
26. The method of claim 21, wherein the compound further
comprises a targeting agent.
27. The method of claim 26, wherein the targeting agent
selected from folate, estrogen, and erlotinib.
28. The method of claim 21, wherein at least one of the
ligands is a therapeutic agent.
29. The method of claim 28, wherein the therapeutic agent
10
is hydroxyquinoline.
30. The method of claim 21, wherein the light includes a
wavelength of about 350 nm to about 1000 nm.
31. The method of claim 21, wherein the light includes a
wavelength of about 500 nm to about 1000 nm.
32. The method of claim 21, wherein m is less than zero. 15
33. The method of claim 21, wherein the site is a tnmor or
in proximity to a tumor.
34. The method of claim 21, wherein the step of administering includes administering the compound by oral administration, transdermal administration, administration by inha- 20
lation, nasal administration, topical administration,
intravaginal administration, ophthalmic administration,
intraaural administration, intracerebral administration, rectal
administration, and parenteral administration, including
injectable such as intravenous administration, intra-arterial 25
administration, intramuscular administration, subcutaneous
administration, or combinations thereof.
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